FDA says Geodon journal ad omits risk info

Share this article:
The FDA says a professional journal ad for Pfizer's antipsychotic medication Geodon (ziprasidone mesylate) for injection omits important risk info and contains unsubstantiated superiority claims. It wants the company to submit a list of all materials to be pulled along with a plan for discontinuing its use, and Pfizer has agreed.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions